Market Overview:
Gaucher disease is a rare inherited disorder caused by deficient
activity of the lysosomal enzyme glucocerebrosidase, which results in excess
accumulation of glucocerebroside in macrophages, particularly in the spleen,
liver, bone marrow, and lung. The signs and symptoms of Gaucher disease include
enlarged liver and spleen, low red blood cell count, easy bruising and
bleedings, bone pain and fractures, swelling and tiredness. Enzyme replacement
therapy (ERT) is the primary treatment for Types 1 and some cases of Type 3
Gaucher disease. The goal of ERT is to slow clinical progression, improve
quality of life and normalize cell and enzyme levels. Therapies such as
velaglucerase alfa, imiglucerase, and taliglucerase alfa are used to treat this
condition by replacing the missing or deficient enzyme.
Market key trends:
One of the key trends in Gaucher disease treatment market is rising number
of patients being diagnosed. With increasing awareness about the disease
symptoms and availability of diagnostic tests, more patients are being
identified worldwide every year. Moreover, ongoing research for development of
newer drug pipeline is also fueling the market growth. For instance, companies
such as Lixte Biotechnology Holdings Inc, JCR Pharmaceuticals Co Ltd, Pharming
Group NV and Orphazyme ApS have drugs in pipeline which are under clinical
trials. This growing pipeline will drive the market upon successful approvals.
Additionally, expansion of geographic availability of therapy is expected to
boost the adoption and increase access to treatment in future.
Porter’s
Analysis
Threat of
new entrants: The threat of new entrants is low for Gaucher disease treatment
due to high capital requirement for R&D, manufacturing, and gaining
regulatory approvals for new drugs. In addition, established manufacturers have
strong brand positioning.
Bargaining power of buyers: The bargaining power of buyers is moderate as there
are only a few approved drugs for Gaucher disease treatment. However, presence
of substitutes and new pipeline drugs limits the buyers' power.
Bargaining power of suppliers: The bargaining power of suppliers is low due to
availability of substitutes for raw materials. In addition, being specialized
treatment, suppliers have limited bargaining power.
Threat of new substitutes: The threat of new substitutes is high due to
significant R&D investments and presence of drugs in late-stage pipeline by
various companies. New and innovative treatment options may erode the market
share of existing drug manufacturers.
Competitive rivalry: The competitive rivalry is high among key players due to
their focus on developing novel therapeutics and targeting new patient
segments.
Key Takeaways
The global
Gaucher
Disease Treatment Market Share is expected to witness high growth,
exhibiting a
CAGR of 2.50% over the
forecast period, due to increasing R&D investments by pharmaceutical
companies and strong product pipeline.
The North America region currently dominates the market and is expected to
continue its dominance during the forecast period. This is attributed to the
growing diagnosis rate, rising government expenditure on healthcare, and
availability of advanced treatment options in the region. However, Asia Pacific
is anticipated to grow at the fastest rate owing to rising healthcare spending
and increasing patient population.
Key players operating in the Gaucher disease treatment market are Genzyme
Corporation, Pfizer, Inc., Shire Human Genetics Therapies, Inc., and Actelion
Pharmaceuticals Ltd. (acquired by Johnson & Johnson in June 2017). There
are various drugs in pipeline of companies such as Lixte Biotechnology Holdings
Inc, JCR Pharmaceuticals Co Ltd, Pharming Group NV and Orphazyme ApS, for
Gaucher disease treatment.
Read More:
https://www.dailyprbulletin.com/gaucher-disease-treatment-market-demand-and-growth/
Comments
Post a Comment